The Quantellect read.As of Nov 20, 2026, 5 active firms cover C4 Therapeutics Inc: 5 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. The target range is very wide, $7.00 to $30.00 (about 4.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $14.75 sits 503% above the current $2.44. The rating mix has stayed broadly stable, with Buy-side ratings easing from 7 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.26 next quarter toward $-0.87 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Buy
Strong Buy00%
Buy5100%
Neutral00%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 20, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$14.75
+503.3% upside
Average target across 4 active firms as of Nov 20, 2026 vs $2.45 current
Highest Target$30.00
Average Target$14.75
Lowest Target$7.00
Detailed analyst forecasts for CCCC
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 20, 2026, 5 of 5 active firms rate CCCC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CCCC EPS & revenue forecast
EPS · NEXT QUARTER
$-0.26
Range $-0.34 – $-0.19 · 3 analysts · +30% YoY
Next period, 3 analysts expect C4 Therapeutics Inc to earn $-0.26 a share (range $-0.34 – $-0.19), versus $-0.20 a year earlier. Full-year consensus is $-0.74, growing to $-0.87 the year after.
REVENUE · NEXT QUARTER
$5.3M
Range $5.0M – $5.8M · 3 analysts · -14% YoY
Revenue is expected to reach $5.3M (range $5.0M – $5.8M), -14.3% year-over-year. Full-year consensus is $26.9M, rising to $23.5M next year.
Top analysts covering C4 Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CCCC.
#1
SL
Sudan Loganathan
Stephens & Co. · Rank #80
Buy
$6.00+145.4% to target
Overall win rate
47%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #171
Buy
$10.00+309.0% to target
Overall win rate
48%
+ Follow
#3
Terence Flynn
Morgan Stanley · Rank #222
Neutral
No targeton CCCC
Overall win rate
36%
+ Follow
#4
Derek Archila
Wells Fargo · Rank #481
Buy
$10.00+309.0% to target
Overall win rate
36%
+ Follow
#5
Etzer Darout
Barclays
Buy
$7.00+186.3% to target
Coverage
—
+ Follow
CCCC stock forecast FAQ
What is CCCC's average 12-month price target?+
The 4 active firms with a live target average $14.75 for C4 Therapeutics Inc over the next 12 months, ranging from a $30.00 high to a $7.00 low, as of Nov 20, 2026.
Is CCCC stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 5 active firms as of Nov 20, 2026, 5 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CCCC?+
The Street-high target is $30.00 (Brookline Capital), and the Street-low is $7.00 (Barclays). The average of all 4 active-firm targets is $14.75.
How many active Wall Street firms cover CCCC?+
5 active firms have a recognized rating on C4 Therapeutics Inc as of Nov 20, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CCCC?+
Among analysts who currently cover CCCC, Sudan Loganathan of Stephens & Co. has the strongest overall Quantellect track record (Rank #80). Their current call is Buy with a $6.00 target.
What is C4 Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.26 per share (range $-0.34 – $-0.19) across 3 analysts. Full-year EPS is projected at $-0.74, rising to $-0.87 the following year.
How much revenue is C4 Therapeutics Inc expected to report next quarter?+
Consensus revenue is $5.3M (range $5.0M – $5.8M). Full-year revenue is projected at $26.9M, growing to $23.5M next year.
Have analysts been upgrading or downgrading CCCC lately?+
As of Nov 20, 2026, 5 of 5 active firms rate CCCC a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CCCC calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.